A Phase 2, Pharmacokinetic Study of the Effects of 6R-BH4 Alone or 6R-BH4 With Vitamin C in Subjects With Endothelial Dysfunction

This study has been completed.
Sponsor:
Information provided by:
BioMarin Pharmaceutical
ClinicalTrials.gov Identifier:
NCT00532844
First received: September 18, 2007
Last updated: April 22, 2009
Last verified: April 2009

September 18, 2007
April 22, 2009
September 2007
November 2008   (final data collection date for primary outcome measure)
Compare plasma BH4 concentrations at the end of each of the 2 treatment regimens in subjects with endothelial dysfunction [ Time Frame: Day 1, Day 14, Day 28 ] [ Designated as safety issue: No ]
Efficacy of 6R-BH4+vit C versus 6R-BH4 alone in increasing BH4 plasma concentrations after a 29-day treatment period in subjects with poorly controlled essential hypertension by measuring plasma concentrations [ Time Frame: 29 days ]
Complete list of historical versions of study NCT00532844 on ClinicalTrials.gov Archive Site
  • Comparison of 6R-BH4+vit C versus 6R-BH4 alone in in terms of plasma concentrations of total biopterins, BH2, B and the ratios BH4:BH2, BH4:BH2+B, BH4:B in subjects with endothelial dysfunction [ Time Frame: Day 1, Day 14, Day 28 ] [ Designated as safety issue: No ]
  • Efficacy of 6R-BH4+vit C versus 6R-BH4 alone in improving endothelial function in subjects with endothelial dysfunction as measured by PAT [ Time Frame: Day 1, Day 13, Day 27 ] [ Designated as safety issue: No ]
  • Efficacy of 6R-BH4+vit C versus 6R-BH4 alone in lowering blood pressure (BP) in subjects with endothelial dysfunction as measured by ABPM [ Time Frame: Day 1, Day 13, Day 27 ] [ Designated as safety issue: No ]
  • Safety of 6R-BH4+vit C versus 6R-BH4 alone in subjects with endothelial dysfunction [ Time Frame: Day 1, Day 13, Day 14, Day 27, Day 28 ] [ Designated as safety issue: Yes ]
  • Efficacy of 6R-BH4+vit C versus 6R-BH4 alone in increasing total biopterins, BH4, BH2, B, BH4:BH2, BH4:BH2+B, BH4:B over a 29-day treatment period in subjects with poorly controlled essential hypertension by measuring plasma concentrations [ Time Frame: 29 days ]
  • Efficacy of 6R-BH4+vit C versus 6R-BH4 alone in improving endothelial function over a 29-day treatment period in subjects with poorly controlled essential hypertension as measured by PAT [ Time Frame: 29 days ]
  • Efficacy of 6R-BH4+vit C versus 6R-BH4 alone in lowering blood pressure (BP) over a 29-day treatment period in subjects with poorly controlled essential hypertension as measured by ABPM [ Time Frame: 29 days ]
  • Safety of 6R-BH4+vit C versus 6R-BH4 alone and the efficacy of 6R-BH4+vit C versus 6R-BH4 alone over a 29-day treatment period in subjects with poorly controlled essential hypertension [ Time Frame: 29 days ]
Not Provided
Not Provided
 
A Phase 2, Pharmacokinetic Study of the Effects of 6R-BH4 Alone or 6R-BH4 With Vitamin C in Subjects With Endothelial Dysfunction
A Phase 2, Randomized, Open-Label, 2-Treatment, 2-Sequence, 2-Period Crossover, Pharmacokinetic (PK) Study to Compare the Plasma Concentrations of BH4 in Subjects With Endothelial Dysfunction Following 14 Days of Treatment by Each of 2 Regimens: 6R-BH4 With Vitamin C and 6R-BH4 Alone

This Phase 2, randomized, open-label, 2-treatment, 2-sequence, 2-period crossover, pharmacokinetic (PK) study will compare plasma concentrations of BH4 in subjects with endothelial dysfunction following 14 days of treatment by each of 2 regimens: 6R-BH4 with vitamin C and 6R-BH4 alone.

Not Provided
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Endothelial Dysfunction
  • Drug: 6R-BH4 (sapropterin dihydrochloride)
    5 mg/kg BID of 6R-BH4 tablets to be administered orally for 13.5 days
  • Drug: 6R-BH4 (sapropterin dihydrochloride)
    5 mg/kg BID of 6R-BH4 tablets, plus 500 mg BID of Vitamin C caplets to be administered orally for 13.5 days
  • Experimental: 6R-BH4
    6R-BH4 5 mg/kg BID for 13.5 days
    Intervention: Drug: 6R-BH4 (sapropterin dihydrochloride)
  • Experimental: 6R-BH4 + Vitamin C
    6R-BH4 5 mg/kg BID + 500 mg Vitamin C BID for 13.5 days
    Intervention: Drug: 6R-BH4 (sapropterin dihydrochloride)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
52
March 2009
November 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Willing and able to provide written, signed informed consent after the nature of the study has been explained, and prior to any research-related procedures.
  • Age is ≥ 18 years and ≤ 75 years.
  • Willing and able to comply with all study procedures.
  • If currently receiving treatment with or taking any of the following supplements, be willing and able to discontinue taking them throughout the treatment period:

    • Vit C supplements
    • Multivitamins containing vit C
    • Any other dietary supplements, nutraceuticals, or other over- the-counter products containing vit C
    • Vitamin E-containing supplements
  • History of cardiovascular disease or cardiovascular risk factors, eg, stable and well-controlled Type 2 diabetes, peripheral arterial disease, obesity, smoking, hypercholesterolemia
  • Endothelial dysfunction, documented at screening by an abnormal PAT of ≤ 1.70.
  • Sexually active subjects must be willing to use an acceptable method of contraception while participating in the study.
  • Females of childbearing potential must have a negative pregnancy test at Screening and be willing to have additional pregnancy tests during the study. Females considered not of childbearing potential include those who have been in menopause at least 2 years, or had tubal ligation at least 1 year prior to screening, or who have had total hysterectomy.

Exclusion Criteria:

  • Hypertension secondary to other medical conditions (e.g., renal failure or steroid usage).
  • Concurrent disease or condition that would interfere with study participation or safety, such as bleeding disorders; history of syncope or vertigo; severe gastroesophageal reflux disease (GERD); heart failure; symptomatic coronary disease; arrhythmia; serious neurologic disorders, including seizures; organ transplant; or organ failure.
  • Type 2 diabetics that are uncontrolled, unstable, newly diagnosed, or have changed therapy in the last three months and all Type 1 diabetics.
  • Any severe comorbid condition that would limit life expectancy to < 6 months.
  • Serum creatinine > 2.0 mg/dL, or hepatic enzyme concentrations > 2 times the upper limit of normal
  • HIV infection, hepatic cirrhosis, other preexisting liver disease, or positive HIV, Hepatitis B or C test at screening.
  • Concomitant treatment with:

    • Drugs known to inhibit folate metabolism (e.g., methotrexate)
    • Levodopa
    • A phosphodiesterase (PDE) 5 inhibitor (e.g., Viagra®, Cialis®, Levitra®, or Revatio®)
    • A PDE 3 inhibitor (e.g., cilostazol, milrinone, or vesnarinone)
  • Use of any investigational product or investigational medical device within 30 days prior to screening, or requirement for any investigational agent prior to completion of all scheduled study assessments.
  • Myocardial infarction, stroke, or surgery within the last 60 days prior to screening.
  • History of alcohol and/or drug abuse or a positive alcohol or drug test at screening.
  • Previous treatment with any formulation of BH4.
  • Has known hypersensitivity to 6R-BH4 or its excipients.
  • Pregnant or breastfeeding at screening, or planning to become pregnant (self or partner) at any time during the study.
  • Any condition that, in the view of the PI, places the subject at high risk of poor treatment compliance or of not completing the study.
Both
18 Years to 75 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00532844
HTN-002
No
BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical
Not Provided
Study Director: Don Nwose, MD BioMarin Pharmaceutical
BioMarin Pharmaceutical
April 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP